CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease - Wikidata - awgldk - TriplyDB

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

http://www.wikidata.org/entity/Q27304608

about

Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Roles of tau protein in health and disease.Chronic exposure to cerebrospinal fluid of multiple system atrophy in neuroblastoma and glioblastoma cells induces cytotoxicity via ER stress and autophagy activation Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature.Plasma α-synuclein predicts cognitive decline in Parkinson's disease.Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.Parkinson disease and cognitive impairment: Five new things.Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.Biomarkers in Neurodegenerative Diseases.Altered Tracer Distribution and Clearance in the Extracellular Space of the Substantia Nigra in a Rodent Model of Parkinson's Disease Disease modification and Neuroprotection in neurodegenerative disorders.Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.Inventory of real world data sources in Parkinson's disease.Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.Tau: A Common Denominator and Therapeutic Target for Neurodegenerative Disorders.

P2860

Q28550937-85C2CB20-501D-46B8-9328-0797A66EB582 Q31097119-5F5ABD25-0E70-433B-BC2F-4595AA8D55B6 Q33559303-8FEF96DD-8F23-4337-B2C8-A70A08719B6D Q35955278-6D467229-8B78-4BEA-AA13-D97436B10B3D Q37494873-3FB3B273-1A8A-4630-8069-15FFD3E2E551 Q38755102-47BADE07-7310-4C36-B66A-DAA781C88900 Q38760749-8BB29663-5C7B-49C3-9E94-FDEEA5032C14 Q38780220-CE9DFE58-5E65-4EAF-AFD1-CEB10D3175D4 Q38853776-7584E2D0-AD34-4445-8881-1C45F811221E Q39009679-19A48765-0601-4259-9523-30F404316295 Q39170813-74E30ED5-2E62-4B96-9D46-0D59511E2501 Q39413097-4B76A6BA-D1A0-4ADD-BFBE-A6AA270350DA Q41108882-3500C950-0135-434A-AEEE-77E81DDEFFDA Q42363882-C7B48919-19DC-4701-A530-040ECE31F0E2 Q45974423-10173A9A-ABE7-4558-BC49-59A5CE485F69 Q47101523-6A965E72-C8A6-41E7-B86A-5BEDECA3AD47 Q47990737-0819A2DB-87C4-44AB-BA34-4A5E52831988 Q48238518-63609C28-A1BF-4EE2-B0FF-45184771E738 Q48949617-FCF5E608-9871-4176-9C56-55F87E9E4C12 Q55027741-E75803A7-CE00-4CCC-93D7-3D96F8D67EFF

P2860

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

http://www.wikidata.org/entity/Q27304608

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@ast

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@en

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@nl

type

label

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@ast

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@en

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@nl

prefLabel

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@ast

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@en

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@nl

P1433

Q27304608-A8E04541-FB8C-4291-9E15-F8BA4334D671

P1476

Q27304608-3840BFAD-5EF4-4B00-AA84-3FC1116B82DE

P2093

Q27304608-1B04F015-BE75-4D8C-B150-9D21293139B7

Q27304608-498EF70C-FB47-49B8-BF43-74E17A460BA8

Q27304608-6291D6C6-00C5-49F6-A562-D5D18BB4011E

Q27304608-B57905A3-F58F-4985-BD11-E279D02C06FC

Q27304608-C27EB472-692B-406F-868F-039B8EE47777

P2860

Q27304608-2B54B297-6705-4D24-868E-F1B17D9EB8EE

Q27304608-317F16C7-4421-4BC4-BEE8-EE53D6527109

Q27304608-33884DD1-969D-4444-9FAF-A1188B5D6946

Q27304608-3AAEB185-FE7D-4657-BFDC-E2FF25FB385C

Q27304608-4155208E-0B76-4021-B65B-F53846BB48BE

Q27304608-4423CBEC-5D3C-4A6A-BB74-3202A85F1337

Q27304608-4AA6922B-C1FA-4847-A8E8-6F2C6767B9D6

Q27304608-5FA9B6F5-DA1D-4263-9180-994F6B2C307B

Q27304608-7729BE73-C97A-481F-85C5-21CD0B2FF373

Q27304608-7BB02DB3-7C66-4421-ADC6-1EED6324A270

P304

Q27304608-2E317058-4255-4D5F-844E-A69088CD2728

P31

Q27304608-2C8CB695-A480-4C89-B964-4E804511CC4A

P356

Q27304608-664E3218-F678-456C-9C22-A0628E4471EA

P407

Q27304608-8A24E0E1-BB02-48CC-909F-831BED8584CD

P433

Q27304608-104EABA5-663F-47C1-882C-A60A711ADB74

P478

Q27304608-BDE61217-02FE-4A65-BF33-2BF159025BF4

P50

Q27304608-A081BAAA-F880-4EB8-BD82-B95AB6AD6BD6

Q27304608-CA596F54-1359-4804-83BB-F5613FF4563B

Q27304608-E3C22EE0-1935-4E0A-A153-9C72FD348094

P577

Q27304608-E5F0A856-4315-4B31-A9F9-4963C3BC5522

P5875

Q27304608-1B1F1467-33C6-4F62-8477-618DD2EFF310

P698

Q27304608-9426EA7E-17E7-4F66-898D-3CF3DAD556F5

P921

Q27304608-12229481-7C56-4738-A60A-69797807A3AD

P932

Q27304608-D7AFD93F-307E-4615-92FA-B6E7D0A86D99

P356

J.PARKRELDIS.2014.12.027

P1433

Parkinsonism and Related Disorders

P1476

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

@en

P2093

Brenna Cholerton

http://www.w3.org/2001/XMLSchema#string

Carmen Ginghina

http://www.w3.org/2001/XMLSchema#string

Kevin C Cain

http://www.w3.org/2001/XMLSchema#string

Parkinson Study Group DATATOP Investigators

http://www.w3.org/2001/XMLSchema#string

Peggy Auinger

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology

“Mini-mental state”

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

P304

271-276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PARKRELDIS.2014.12.027

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271330211

http://www.w3.org/2001/XMLSchema#string

P698

25596881

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4603566

http://www.w3.org/2001/XMLSchema#string